Pelabresib联合芦可替尼对比JAK抑制剂单药治疗骨髓纤维化的匹配调整间接比较
该研究采用非锚定匹配调整间接比较,在JAK抑制剂初治的骨髓纤维化患者中,将MANIFEST研究第3臂的Pelabresib联合芦可替尼与COMFORT-I、COMFORT-II、SIMPLIFY-1和JAKARTA研究中JAK抑制剂单药的数据进行比较。第24周时,联合治疗组在脾脏体积缩小35%和总症状评分降低50%的缓解率比值均大于1,总症状评分改善最早见于第12周且持久。结果提示Pelabresib联合芦可替尼在JAK抑制剂初治骨髓纤维化患者中可能具有比JAK抑制剂单药更高的疗效。
要点
- 第24周时,Pelabresib联合芦可替尼对比所有对照药物,脾脏体积缩小35%和总症状评分降低50%的缓解率比值均大于1。
- 总症状评分改善最早在第12周观察到,且疗效持久。
- 结果提示Pelabresib联合芦可替尼在JAK抑制剂初治骨髓纤维化患者中可能比JAK抑制剂单药疗效更高。
核心结论
- Pelabresib联合芦可替尼在JAK抑制剂初治骨髓纤维化患者中可能具有比JAK抑制剂单药更高的疗效。
研究设计与样本
- 非锚定匹配调整间接比较分析,比较MANIFEST研究第3臂(Pelabresib联合芦可替尼治疗JAK抑制剂初治骨髓纤维化患者)与COMFORT-I、COMFORT-II、SIMPLIFY-1和JAKARTA研究中JAK抑制剂单药治疗JAK抑制剂初治患者的数据。
主要发现
- 第24周时,Pelabresib联合芦可替尼对比所有对照药物,脾脏体积缩小35%和总症状评分降低50%的缓解率比值均大于1。
- 总症状评分改善最早在第12周观察到,且疗效持久。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Janus kinase inhibitors (JAKis) ruxolitinib, fedratinib, and pacritinib are the current standard of care in symptomatic myelofibrosis (MF). However, progressive disease and toxicities frequently lead to JAKi discontinuation. Preclinical data indicate that combining JAK and bromodomain and extraterminal (BET) domain inhibition leads to overlapping effects in MF. Pelabresib (CPI-0610), an oral, small-molecule BET1,2 inhibitor (BETi), in combination with ruxolitinib showed improvements in spleen volume reduction (SVR35) and total symptom score reduction (TSS50) from baseline in the phase 2 MANIFEST study (NCT02158858) in patients with MF. Given the absence of a head-to-head clinical comparison between JAKi monotherapy and JAKi with BETi combination therapy, we performed an unanchored matching-adjusted indirect comparison analysis to adjust for differences between studies and allow for the comparison of SVR35, TSS50, and TSS measured at several timepoints in arm 3 of MANIFEST (pelabresib with ruxolitinib in JAKi treatment-naive patients with MF), with data from the following JAKi monotherapy studies in JAKi treatment-naive patients: COMFORT-I and COMFORT-II (ruxolitinib), SIMPLIFY-1 (ruxolitinib and momelotinib), and JAKARTA (fedratinib). Response rate ratios >1 were observed for pelabresib with ruxolitinib vs all comparators for SVR35 and TSS50 at week 24. Improvements in TSS were observed as early as week 12 and were durable. These results indicate that pelabresib with ruxolitinib may have a potentially higher efficacy than JAKi monotherapy in JAKi treatment-naive MF.
引用
- Gupta V, Mascarenhas J, Kremyanskaya M, et al. Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis. Blood Adv. 2023. PMID: 37530627. doi:10.1182/bloodadvances.2023010628
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。